High-throughput identification of chemical inhibitors of E. coli group 2 capsule biogenesis as anti-virulence agents

Carlos C. Goller, Patrick C. Seed

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Rising antibiotic resistance among Escherichia coli, the leading cause of urinary tract infections (UTIs), has placed a new focus on molecular pathogenesis studies, aiming to identify new therapeutic targets. Anti-virulence agents are attractive as chemotherapeutics to attenuate an organism during disease but not necessarily during benign commensalism, thus decreasing the stress on beneficial microbial communities and lessening the emergence of resistance. We and others have demonstrated that the K antigen capsule of E. coli is a preeminent virulence determinant during UTI and more invasive diseases. Components of assembly and export are highly conserved among the major K antigen capsular types associated with UTI-causing E. coli and are distinct from the capsule biogenesis machinery of many commensal E. coli, making these attractive therapeutic targets. We conducted a screen for anti-capsular small molecules and identified an agent designated "C7" that blocks the production of K1 and K5 capsules, unrelated polysaccharide types among the Group 2-3 capsules. Herein lies proof-of-concept that this screen may be implemented with larger chemical libraries to identify secondgeneration small-molecule inhibitors of capsule biogenesis. These inhibitors will lead to a better understanding of capsule biogenesis and may represent a new class of therapeutics.

Original languageEnglish (US)
Article numbere11642
JournalPLoS One
Volume5
Issue number7
DOIs
StatePublished - Jul 19 2010

Fingerprint

chemical inhibitors
urinary tract diseases
Escherichia coli
Capsules
Virulence
virulence
Throughput
Urinary Tract Infections
therapeutics
commensalism
antigens
antibiotic resistance
Small Molecule Libraries
microbial communities
Molecules
polysaccharides
Symbiosis
pathogenesis
Microbial Drug Resistance
Machinery

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{a144c96fedd04b92834ce6de9ad4aec0,
title = "High-throughput identification of chemical inhibitors of E. coli group 2 capsule biogenesis as anti-virulence agents",
abstract = "Rising antibiotic resistance among Escherichia coli, the leading cause of urinary tract infections (UTIs), has placed a new focus on molecular pathogenesis studies, aiming to identify new therapeutic targets. Anti-virulence agents are attractive as chemotherapeutics to attenuate an organism during disease but not necessarily during benign commensalism, thus decreasing the stress on beneficial microbial communities and lessening the emergence of resistance. We and others have demonstrated that the K antigen capsule of E. coli is a preeminent virulence determinant during UTI and more invasive diseases. Components of assembly and export are highly conserved among the major K antigen capsular types associated with UTI-causing E. coli and are distinct from the capsule biogenesis machinery of many commensal E. coli, making these attractive therapeutic targets. We conducted a screen for anti-capsular small molecules and identified an agent designated {"}C7{"} that blocks the production of K1 and K5 capsules, unrelated polysaccharide types among the Group 2-3 capsules. Herein lies proof-of-concept that this screen may be implemented with larger chemical libraries to identify secondgeneration small-molecule inhibitors of capsule biogenesis. These inhibitors will lead to a better understanding of capsule biogenesis and may represent a new class of therapeutics.",
author = "Goller, {Carlos C.} and Seed, {Patrick C.}",
year = "2010",
month = "7",
day = "19",
doi = "10.1371/journal.pone.0011642",
language = "English (US)",
volume = "5",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

High-throughput identification of chemical inhibitors of E. coli group 2 capsule biogenesis as anti-virulence agents. / Goller, Carlos C.; Seed, Patrick C.

In: PLoS One, Vol. 5, No. 7, e11642, 19.07.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High-throughput identification of chemical inhibitors of E. coli group 2 capsule biogenesis as anti-virulence agents

AU - Goller, Carlos C.

AU - Seed, Patrick C.

PY - 2010/7/19

Y1 - 2010/7/19

N2 - Rising antibiotic resistance among Escherichia coli, the leading cause of urinary tract infections (UTIs), has placed a new focus on molecular pathogenesis studies, aiming to identify new therapeutic targets. Anti-virulence agents are attractive as chemotherapeutics to attenuate an organism during disease but not necessarily during benign commensalism, thus decreasing the stress on beneficial microbial communities and lessening the emergence of resistance. We and others have demonstrated that the K antigen capsule of E. coli is a preeminent virulence determinant during UTI and more invasive diseases. Components of assembly and export are highly conserved among the major K antigen capsular types associated with UTI-causing E. coli and are distinct from the capsule biogenesis machinery of many commensal E. coli, making these attractive therapeutic targets. We conducted a screen for anti-capsular small molecules and identified an agent designated "C7" that blocks the production of K1 and K5 capsules, unrelated polysaccharide types among the Group 2-3 capsules. Herein lies proof-of-concept that this screen may be implemented with larger chemical libraries to identify secondgeneration small-molecule inhibitors of capsule biogenesis. These inhibitors will lead to a better understanding of capsule biogenesis and may represent a new class of therapeutics.

AB - Rising antibiotic resistance among Escherichia coli, the leading cause of urinary tract infections (UTIs), has placed a new focus on molecular pathogenesis studies, aiming to identify new therapeutic targets. Anti-virulence agents are attractive as chemotherapeutics to attenuate an organism during disease but not necessarily during benign commensalism, thus decreasing the stress on beneficial microbial communities and lessening the emergence of resistance. We and others have demonstrated that the K antigen capsule of E. coli is a preeminent virulence determinant during UTI and more invasive diseases. Components of assembly and export are highly conserved among the major K antigen capsular types associated with UTI-causing E. coli and are distinct from the capsule biogenesis machinery of many commensal E. coli, making these attractive therapeutic targets. We conducted a screen for anti-capsular small molecules and identified an agent designated "C7" that blocks the production of K1 and K5 capsules, unrelated polysaccharide types among the Group 2-3 capsules. Herein lies proof-of-concept that this screen may be implemented with larger chemical libraries to identify secondgeneration small-molecule inhibitors of capsule biogenesis. These inhibitors will lead to a better understanding of capsule biogenesis and may represent a new class of therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=77955397284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955397284&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0011642

DO - 10.1371/journal.pone.0011642

M3 - Article

C2 - 20657847

AN - SCOPUS:77955397284

VL - 5

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e11642

ER -